Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Depreciation & Amortization (CF) (2016 - 2025)

Karyopharm Therapeutics filings provide 14 years of Depreciation & Amortization (CF) readings, the most recent being $19000.0 for Q4 2025.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 76.54% to $19000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $296000.0, a 12.94% decrease, with the full-year FY2025 number at $296000.0, down 12.94% from a year prior.
  • Depreciation & Amortization (CF) hit $19000.0 in Q4 2025 for Karyopharm Therapeutics, down from $121000.0 in the prior quarter.
  • In the past five years, Depreciation & Amortization (CF) ranged from a high of $290000.0 in Q1 2023 to a low of $19000.0 in Q4 2025.
  • Median Depreciation & Amortization (CF) over the past 5 years was $102000.0 (2022), compared with a mean of $128800.0.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 63.84% in 2023 and later plummeted 76.54% in 2025.
  • Karyopharm Therapeutics' Depreciation & Amortization (CF) stood at $139000.0 in 2021, then fell by 18.71% to $113000.0 in 2022, then crashed by 31.86% to $77000.0 in 2023, then increased by 5.19% to $81000.0 in 2024, then crashed by 76.54% to $19000.0 in 2025.
  • The last three reported values for Depreciation & Amortization (CF) were $19000.0 (Q4 2025), $121000.0 (Q3 2025), and $78000.0 (Q2 2025) per Business Quant data.